The global medical community is actively reconsidering how polycystic ovary syndrome (PCOS) is named and discussed—a change with important implications for patients and healthcare providers alike. Three critical facts underscore why this reform matters: first, 170 million women worldwide are affected by this condition, making terminology accuracy essential for public health awareness. Second, the current name contributes to diagnostic delays averaging 2.3 years, delaying crucial treatment and support for affected individuals.
Third, major medical organizations including the Endocrine Society are actively reviewing alternative terminology—such as “metabolic reproductive syndrome”—that would better reflect PCOS as a systemic hormonal and metabolic disorder rather than a primarily ovarian condition. This shift in language could significantly improve how healthcare providers recognize and diagnose PCOS, particularly in patients who do not present with the stereotypical ovarian cyst presentation.
For patients seeking care and providers delivering it, understanding this terminology evolution is vital to ensuring timely diagnosis and comprehensive, evidence-based treatment approaches.
Read the full article on GMJ Newsroom.
Was this article helpful?
